Dynavax, Vaxart Enter Exclusive Global License Agreement for Novel Oral COVID-19 Vaccine
Under the terms of the agreement, Dynavax will receive exclusive, worldwide rights to develop and commercialise oral COVID-19 vaccines based on Vaxart’s delivery platform.
Dynavax | 06/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy